Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Societal CDMO stock price, quote, forecast and news

SCTL
US75629F1093
A1XFAV

Price

1.10
Today +/-
+0
Today %
+0 %
P

Societal CDMO stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Societal CDMO stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Societal CDMO stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Societal CDMO stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Societal CDMO's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Societal CDMO Stock Price History

DateSocietal CDMO Price
4/8/20241.10 undefined
4/5/20241.10 undefined

Societal CDMO Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Societal CDMO, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Societal CDMO from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Societal CDMO’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Societal CDMO. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Societal CDMO’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Societal CDMO’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Societal CDMO’s growth potential.

Societal CDMO Revenue, EBIT and net profit per share

DateSocietal CDMO RevenueSocietal CDMO EBITSocietal CDMO Net Income
2029e167.85 M undefined0 undefined0 undefined
2028e145.95 M undefined25.54 M undefined0 undefined
2027e126.92 M undefined19.04 M undefined0 undefined
2026e112.82 M undefined11.28 M undefined4.31 M undefined
2025e103.44 M undefined2.78 M undefined-6.47 M undefined
2024e96.82 M undefined-1.32 M undefined-9.16 M undefined
202394.64 M undefined-3.57 M undefined-13.27 M undefined
202290.21 M undefined280,000 undefined-19.88 M undefined
202175.36 M undefined410,000 undefined-11.37 M undefined
202066.5 M undefined-8.34 M undefined-27.5 M undefined
201999.22 M undefined23.63 M undefined-18.63 M undefined
201877.35 M undefined-54.04 M undefined-79.72 M undefined
201771.83 M undefined-40.31 M undefined-50.08 M undefined
201669.34 M undefined-25.77 M undefined-30.21 M undefined
201551.95 M undefined-6.97 M undefined3.03 M undefined
20140 undefined-11.87 M undefined-17.4 M undefined
20130 undefined-1.09 M undefined-2.4 M undefined
20120 undefined-880,000 undefined-1.95 M undefined
20110 undefined-2.31 M undefined-3.25 M undefined

Societal CDMO Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000051697177996675909496103112126145167
-----35.292.908.4528.57-33.3313.6420.004.442.137.298.7412.5015.0815.17
----45.1046.3846.4844.1648.4818.1825.3325.5619.15------
0000233233344812192318000000
-20-1-11-6-25-40-5423-800-3-121119250
-----11.76-36.23-56.34-70.1323.23-12.12---3.19-1.041.949.8215.0817.24-
-3-1-2-173-30-50-79-18-27-11-19-13-9-64000
--66.67100.00750.00-117.65-1,100.0066.6758.00-77.2250.00-59.2672.73-31.58-30.77-33.33-166.67---
5.385.385.386.248.7510.7219.0720.4722.4123.7444.1257.8895.23000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Societal CDMO Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Societal CDMO is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
00.1019.719.864.564.538.519.123.825.2158.1
00008.610.49.718.123.216.420.524.729.41
0000000000000
000098.79.810.715.111.68.910.310.26
000.80.61.31.13.33.92.72.32.95.65.69
00.10.820.338.784.787.371.260.154.157.555.653.46
000037.937.339.145.642.744.357.655.954.8
0000000000000
0000000000000
00004037.434.932.33.30.73.82.92.24
00006.46.46.46.44.34.341.141.141.08
000015.617.118.60000.221.9
000099.998.29984.350.349.3102.7101.9100.01
00.10.820.3138.6182.9186.3155.5110.4103.4160.2157.5153.47
                         
55.45.90.10.10.20.20.20.20.30.55.21.05
00052.971.3132.7140168.5199.9220287.4320.3336.52
-13.6-15.6-18-34.1-31.1-61.3-111.3-188.3-206.9-234.4-245.8-265.6-278.91
0000000000000
0000000000000
-8.6-10.2-12.118.940.371.628.9-19.6-6.8-14.142.159.958.66
0.200.40.91.64.184.511.82.11.51.31
0.30.10.60.63.39.29.414.143.111.311.611.38
00000.10.732.610.41.51.42.32.20.54
8.110.211.90000000000
00004.52.20001.527.636.76
8.610.312.91.59.516.250296.57.817.722.949.99
000025.222.253.664.2110.3108.195.5310.34
0000000000000
000063.67353.981.70.41.6543.844.49
000088.895.2107.5145.9110.7109.7100.574.844.82
8.610.312.91.598.3111.4157.5174.9117.2117.5118.297.794.81
00.10.820.4138.6183186.4155.3110.4103.4160.3157.6153.47
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Societal CDMO provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Societal CDMO's financial health and stability.

Assets

Societal CDMO's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Societal CDMO must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Societal CDMO after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Societal CDMO's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-2-1-1-163-30-50-79-18-27-11-19-13
0000677788788
0000-15-1-11700010
0000760-6-10115-8-3
000510183121125152012
0000445814137128
0000000000000
-2-10-108-3-17-43-25810-3-1
0000-2-3-6-10-8-7-5-8-8
0000-55-3-10-7-9-7-29-8-8
0000-520-33-10-2400
0000000000000
210033-6281043-5-10-66-1
00030050018-131132336
21030465123271541912
0000127-4-1-14-1-234-2
0000000000000
00019044-3-22-1941-10-6
-2.17-1.22-0.82-10.876.05-6.97-23.73-53.73-33.840.475.57-11.99-9.24
0000000000000

Societal CDMO stock margins

The Societal CDMO margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Societal CDMO. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Societal CDMO.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Societal CDMO's sales revenue. A higher gross margin percentage indicates that the Societal CDMO retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Societal CDMO's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Societal CDMO's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Societal CDMO's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Societal CDMO. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Societal CDMO's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Societal CDMO Margin History

Societal CDMO Gross marginSocietal CDMO Profit marginSocietal CDMO EBIT marginSocietal CDMO Profit margin
2029e19.17 %0 %0 %
2028e19.17 %17.5 %0 %
2027e19.17 %15 %0 %
2026e19.17 %10 %3.82 %
2025e19.17 %2.69 %-6.25 %
2024e19.17 %-1.36 %-9.46 %
202319.17 %-3.78 %-14.03 %
202225.65 %0.31 %-22.04 %
202126.3 %0.54 %-15.09 %
202018.6 %-12.54 %-41.35 %
201948.62 %23.82 %-18.78 %
201844.2 %-69.86 %-103.06 %
201746.83 %-56.12 %-69.72 %
201646.42 %-37.16 %-43.57 %
201546.01 %-13.42 %5.83 %
201419.17 %0 %0 %
201319.17 %0 %0 %
201219.17 %0 %0 %
201119.17 %0 %0 %

Societal CDMO Stock Sales Revenue, EBIT, Earnings per Share

The Societal CDMO earnings per share therefore indicates how much revenue Societal CDMO has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Societal CDMO earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Societal CDMO's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Societal CDMO’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Societal CDMO's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Societal CDMO Revenue, EBIT and net profit per share

DateSocietal CDMO Sales per ShareSocietal CDMO EBIT per shareSocietal CDMO Earnings per Share
2029e1.59 undefined0 undefined0 undefined
2028e1.38 undefined0 undefined0 undefined
2027e1.2 undefined0 undefined0 undefined
2026e1.07 undefined0 undefined0.04 undefined
2025e0.98 undefined0 undefined-0.06 undefined
2024e0.92 undefined0 undefined-0.09 undefined
20230.99 undefined-0.04 undefined-0.14 undefined
20221.56 undefined0 undefined-0.34 undefined
20211.71 undefined0.01 undefined-0.26 undefined
20202.8 undefined-0.35 undefined-1.16 undefined
20194.43 undefined1.05 undefined-0.83 undefined
20183.78 undefined-2.64 undefined-3.89 undefined
20173.77 undefined-2.11 undefined-2.63 undefined
20166.47 undefined-2.4 undefined-2.82 undefined
20155.94 undefined-0.8 undefined0.35 undefined
20140 undefined-1.9 undefined-2.79 undefined
20130 undefined-0.2 undefined-0.45 undefined
20120 undefined-0.16 undefined-0.36 undefined
20110 undefined-0.43 undefined-0.6 undefined

Societal CDMO business model

Recro Pharma Inc. is a company operating in the biopharmaceutical industry, specializing in the development and marketing of innovative therapeutics. The company is based in Malvern, Pennsylvania, USA, and was founded in 2007. The history of Recro Pharma Inc. dates back to 1985, when the company was founded as ReceptoPharm. In 2008, it was renamed Recro Pharma Inc. to emphasize its focus on pharmaceutical activities. Since then, the company has made significant progress, including successful clinical trials and the introduction of innovative products. Recro Pharma follows a business model based on the development of therapeutics in the areas of pain management and anesthesia. The company aims to create solutions to alleviate pain in patients and improve their quality of life. Recro Pharma's goal is to bring high-quality products to the market that are distinguished by excellent safety, efficacy, and patient tolerance. Recro Pharma's product range currently includes two main areas. Firstly, the company has launched its medication Meloxicam for pain treatment in adults. Secondly, it has developed and distributes a portfolio of anesthesia-related therapeutics through its subsidiary Lumendi LLC. Meloxicam is a non-steroidal anti-inflammatory drug used for pain relief in adults. The medication is available in various forms such as tablets and capsules and is used in both hospital and outpatient care. Lumendi LLC specializes in the development and distribution of anesthesia-related therapeutics. The company's products include those for intubation and muscle relaxation in surgical procedures, as well as anesthesia for pain management. Lumendi's goal is to create innovative solutions to improve medical practice and shorten hospital stays. Recro Pharma Inc. aims to expand its product range through the development of further innovative solutions. The company continues to invest in research and development to develop new products and strengthen its position in the market. In 2020, Recro Pharma Inc. received FDA approval for the product IV Meloxicam. This is an intravenous form of the drug Meloxicam used for pain treatment in adults. This is a significant milestone for the company as it is now able to offer an alternative form of the medication. Recro Pharma Inc. has established itself as a significant player in the biopharmaceutical industry. The company aspires to further strengthen its position in the market and create innovative solutions to improve medical practice. With its high-quality products, Recro Pharma contributes to alleviating patients' pain and improving their quality of life. Societal CDMO is one of the most popular companies on Eulerpool.com.

Societal CDMO SWOT Analysis

Strengths

Recro Pharma Inc has a strong portfolio of innovative pharmaceutical products, allowing them to compete effectively in the market.

The company has a highly skilled and experienced research and development team, which enables them to continuously develop and launch new drugs.

Weaknesses

Recro Pharma Inc relies heavily on a few key products for a significant portion of their revenue, making them vulnerable to changes in market demand.

The company has a limited global presence compared to some of its competitors, which restricts its ability to access international markets.

Opportunities

The pharmaceutical industry is experiencing rapid growth, presenting an opportunity for Recro Pharma Inc to expand its market share and generate increased revenue.

There is a growing demand for personalized medicine, which opens up opportunities for Recro Pharma Inc to develop targeted therapies.

Threats

The pharmaceutical industry is highly regulated, and changes in regulations can pose challenges for Recro Pharma Inc in terms of compliance and product development.

Competition within the pharmaceutical industry is intense, with multiple players vying for market share, thereby increasing the threat of price wars and margin pressures.

Societal CDMO Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Societal CDMO historical P/E ratio, EBIT, and P/S ratio.

Societal CDMO shares outstanding

The number of shares was Societal CDMO in 2023 — This indicates how many shares 95.229 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Societal CDMO earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Societal CDMO's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Societal CDMO’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Societal CDMO's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Societal CDMO.

Societal CDMO latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2023-0.01 -0.01  (1.96 %)2023 Q4
9/30/2023-0.02 -0.05  (-145.1 %)2023 Q3
6/30/2023-0.03 -0.04  (-17.65 %)2023 Q2
3/31/2023-0.05 -0.06  (-17.65 %)2023 Q1
12/31/2022-0.07 -0.07  (5.41 %)2022 Q4
9/30/2022-0.06 -0.06  (5.96 %)2022 Q3
6/30/2022-0.09 -0.06  (29.41 %)2022 Q2
3/31/2022-0.09 -0.08  (12.85 %)2022 Q1
12/31/2021-0.07 -0.04  (41.18 %)2021 Q4
9/30/2021-0.07 -0.07  (6.42 %)2021 Q3
1
2
3
4

Eulerpool ESG Scorecard© for the Societal CDMO stock

Eulerpool World ESG Rating (EESG©)

27/ 100

🌱 Environment

17

👫 Social

40

🏛️ Governance

24

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Societal CDMO list of shareholders

%
Name
Stocks
Change
Date
9.78414 % Lytton (Laurence W)10,340,8583,847,16812/31/2023
8.46149 % Beryl Capital Management, LLC8,942,9468,942,9463/20/2024
6.83737 % AWM Investment Company, Inc.7,226,414-3,039,73012/31/2023
4.73082 % Gerald Joseph Yakatan & Una Yakatan Family Trust5,000,00003/20/2023
4.02046 % Driehaus Capital Management, LLC4,249,229012/31/2023
3.76927 % Railroad Ranch Capital Management, LLC3,983,737-34,60212/14/2022
3.11608 % Royce Investment Partners3,293,3828,30012/31/2023
25.48619 % CoreRx, Inc.26,936,34926,936,3492/28/2024
2.90472 % Samjo Capital, LLC3,070,000-4,969,10012/31/2023
2.89225 % The Vanguard Group, Inc.3,056,819012/31/2023
1
2
3
4
5
...
10

Societal CDMO Executives and Management Board

Mr. J. David Enloe59
Societal CDMO President, Chief Executive Officer, Director (since 2020)
Compensation 2.27 M
Mr. Ryan Lake45
Societal CDMO Chief Financial Officer
Compensation 1.42 M
Mr. Wayne Weisman67
Societal CDMO Executive Chairman of the Board (since 2008)
Compensation 219,894
Mr. William Ashton72
Societal CDMO Independent Director
Compensation 194,894
Mr. Bryan Reasons55
Societal CDMO Independent Director
Compensation 194,894
1
2
3

Societal CDMO Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Teva Pharmaceutical Inds Stock
Teva Pharmaceutical Inds
SupplierCustomer0,460,93----
BioCorRx Stock
BioCorRx
SupplierCustomer0,390,30----
Advanz Pharma Corp. Ltd. Stock
Advanz Pharma Corp. Ltd.
SupplierCustomer0,14-0,62----
Ensysce Biosciences Stock
Ensysce Biosciences
SupplierCustomer0,110,26----
Lannett Stock
Lannett
SupplierCustomer0,030,78----
Novartis Stock
Novartis
SupplierCustomer-0,100,30----
Otsuka Holdings Stock
Otsuka Holdings
SupplierCustomer-0,60-0,30----
1

Most common questions regarding Societal CDMO

What values and corporate philosophy does Societal CDMO represent?

Recro Pharma Inc represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Recro Pharma is dedicated to developing and delivering high-quality medications to patients in need. The company's corporate philosophy emphasizes delivering innovative drug solutions that meet the highest standards of safety and efficacy. Recro Pharma is committed to conducting business ethically and maintaining strong relationships with healthcare professionals, patients, and stakeholders. Through its dedication to research and development, Recro Pharma aims to improve patient outcomes and enhance the quality of life for individuals around the world.

In which countries and regions is Societal CDMO primarily present?

Recro Pharma Inc primarily operates in the United States.

What significant milestones has the company Societal CDMO achieved?

Recro Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for its lead product, IV meloxicam, a non-opioid pain management option. They also secured a licensing agreement for IV meloxicam with Baudax Bio Inc and expanded its use to multiple surgical indications. In addition, Recro Pharma Inc successfully completed a Phase III clinical trial for a new treatment option targeting postoperative pain. The company continues to focus on research and development to provide innovative solutions for patients and healthcare professionals. Recro Pharma Inc's achievements highlight their commitment to advancing pain management and improving patient outcomes.

What is the history and background of the company Societal CDMO?

Recro Pharma Inc is a pharmaceutical company with a rich history and background. Established in 2007, the company is based in Malvern, Pennsylvania. Recro Pharma specializes in developing and commercializing innovative therapies for acute care settings. They focus on creating non-opioid pain management solutions, addressing the growing need for safer and more effective alternatives. The company's dedicated team of scientists and researchers work diligently to provide patients with advanced pharmaceutical products. Recro Pharma's commitment to excellence and dedication to improving patient outcomes has earned them a reputable position in the pharmaceutical industry.

Who are the main competitors of Societal CDMO in the market?

The main competitors of Recro Pharma Inc in the market include companies such as Mallinckrodt Pharmaceuticals, Pfizer Inc, and Amneal Pharmaceuticals.

In which industries is Societal CDMO primarily active?

Recro Pharma Inc is primarily active in the pharmaceutical industry.

What is the business model of Societal CDMO?

Recro Pharma Inc operates as a specialty pharmaceutical company. Its business model involves developing and commercializing innovative products for hospital and ambulatory care settings. Recro Pharma focuses on therapies that address pain management, acute care, and other medical needs. By leveraging its expertise in formulation and manufacturing, the company aims to provide advanced solutions to healthcare professionals and patients. With a commitment to delivering high-quality pharmaceuticals, Recro Pharma Inc continues to contribute to the improvement of patient outcomes and enhance medical treatment options.

What is the P/E ratio of Societal CDMO 2024?

The Societal CDMO P/E ratio is -11.43.

What is the P/S ratio of Societal CDMO 2024?

The Societal CDMO P/S ratio is 1.08.

What is the AlleAktien quality score of Societal CDMO?

The AlleAktien quality score for Societal CDMO is 3/10.

What is the revenue of Societal CDMO 2024?

The expected Societal CDMO revenue is 96.82 M USD.

How high is the profit of Societal CDMO 2024?

The expected Societal CDMO profit is -9.16 M USD.

What is the business model of Societal CDMO

Recro Pharma Inc. is a biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative drugs to improve the health and well-being of patients worldwide. The company has three main divisions: Acute Care, Contract Development and Manufacturing Organization (CDMO), and Healthcare. Within the Acute Care division, the company has a portfolio of pain treatment drugs, including intravenous (IV) acetaminophen injections, methoxyflurane inhalers, and sublingual sufentanil tablets. The CDMO division offers manufacturing services for customers in the biotechnology and pharmaceutical industries. These services include process development and optimization, clinical and commercial manufacturing, stability studies, and quality assurance services. Recro Pharma's Healthcare division focuses on developing products to enhance patient care and safety. For example, the company is currently developing a novel nasal spray for the treatment of severe opioid overdoses. Recro Pharma relies on collaboration with partners and acquisitions of companies that complement its capabilities and processes necessary to create new solutions in the pharmaceutical products and services field. For example, the company was acquired by Alkermes plc in 2015 to acquire specialized formulation expertise and production capacity to complement its own resources. Recro Pharma's business model is based on focusing on continuous improvement of treatment options and patient care through innovative and effective drugs and services that are at the forefront of technology. The company intends to expand its drug development platform through technology partnerships, licensing of intellectual property, and acquisitions of companies to bring future products to market faster and more effectively. Overall, Recro Pharma has become a significant player in the pharmaceutical industry, catering to the needs of physicians, patients, and OEMs worldwide. Recro Pharma offers a wide range of innovative drugs and services that contribute to better healthcare and higher patient satisfaction.

What is the Societal CDMO dividend?

Societal CDMO pays a dividend of 0 USD distributed over payouts per year.

How often does Societal CDMO pay dividends?

The dividend cannot currently be calculated for Societal CDMO or the company does not pay out a dividend.

What is the Societal CDMO ISIN?

The ISIN of Societal CDMO is US75629F1093.

What is the Societal CDMO WKN?

The WKN of Societal CDMO is A1XFAV.

What is the Societal CDMO ticker?

The ticker of Societal CDMO is SCTL.

How much dividend does Societal CDMO pay?

Over the past 12 months, Societal CDMO paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Societal CDMO is expected to pay a dividend of 0 USD.

What is the dividend yield of Societal CDMO?

The current dividend yield of Societal CDMO is .

When does Societal CDMO pay dividends?

Societal CDMO pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Societal CDMO?

Societal CDMO paid dividends every year for the past 0 years.

What is the dividend of Societal CDMO?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Societal CDMO located?

Societal CDMO is assigned to the 'Health' sector.

Wann musste ich die Aktien von Societal CDMO kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Societal CDMO from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Societal CDMO pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Societal CDMO in the year 2023?

In the year 2023, Societal CDMO distributed 0 USD as dividends.

In which currency does Societal CDMO pay out the dividend?

The dividends of Societal CDMO are distributed in USD.

All fundamentals about Societal CDMO

Our stock analysis for Societal CDMO Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Societal CDMO Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.